Promoter holding
64.27%
GP
Gland Pharma Ltd - Due diligence report
A 360° intelligence report on Gland Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signals -…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Gland Pharma — 360° Intelligence Report
Generated from MCA filings & public records76/100
Trust Score
Low Risk
Gland Pharma is assessed as Low Risk with a Trust Score of 76/100. Gland Pharma is an active public limited indian non-government company incorporated in 1978, operating in the Healthcare sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 03 Jul 2026 from the latest processed filings. Gland Pharma Ltd snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
76/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
80/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
75/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
75/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreCaution Indicated
45/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
80/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 75/100 Low Risk
- No open charges - unencumbered balance sheet.
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 0 open (-) · 11 satisfied (566.83 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Syndicate Bank | 5 | 48.0 cr |
| The Bank Of Nova Scotia | 1 | 48.0 cr |
| Icici Bank Limited | 1 | 48.0 cr |
| Export Import Bank Of India | 3 | 48.0 cr |
| Technology Development Board | 1 | 48.0 cr |
Compliance Score: 80/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 3 court forum(s).
- 8 active GST registration(s).
Legal cases on record (3)
05
Director Intelligence
Stability score: 45/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| ESSAJI GOOLAM VAHANVATI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| UDO JAHANNES VETTER | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| JIA AI ZHANG | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SRINIVAS SADU | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NAINA LAL KIDWAI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SAMPATH KUMAR PALLERLAMUDI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAVI SHEKHAR MITRA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SHYAMAKANT BINDA GIRI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SATYANARAYANA MURTHY CHAVALI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Wenjie Zhang | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Wei Huang | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SRINIVAS SADU | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Shyamakant Binda Giri | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 13 directors on the board.
- JIA AI ZHANG has DIN status "Deactivated due to non-filing of DIR-3 KYC".
- 1 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Fosun Pharma Industrial Pte Ltd
Subsidiaries
-
Group entities
-
Capital events
3 allotment(s) · 0 transfer(s)
Promoters hold a minority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Gland Pharma International Pte Ltd. | Subsidiary Company | 74.00% |
| Gland Pharma Usa Inc | Subsidiary Company | 74.00% |
| Fosun Pharma Industrial Pte Ltd | Holding Company | 74.00% |
Key managerial personnel: SRINIVAS SADU (CEO) · RAVI SHEKHAR MITRA (CFO) · SHYAMAKANT BINDA GIRI (CEO) · SRINIVAS SADU (Whole-time director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 80 · Distress 75
Growth signals & trust indicators
Steady revenue growth: +38% over 4 year(s).
Profit expanded 1.42 year-on-year.
Net margin improved to 2.1x.
EPFO headcount growing - hiring signal.
Operating for 48+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
3 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence77/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment76/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- No existing security registered - first-charge position available.
- Compliance record supports lending.
Investor view77/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 4 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management churn warrants questions.
09
MCA Filings & Events Timeline
Latest 15 events28 Aug 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
04 Feb 2025
Director appointed
Shyamakant Binda Giri (Ceo)
16 Jan 2025
Director appointed
SHYAMAKANT BINDA GIRI (CEO)
07 Dec 2024
Director ceased
Wei Huang
04 Nov 2024
Director appointed
Wei Huang (Director)
30 Aug 2024
Director appointed
Wenjie Zhang (Director)
24 Nov 2022
Securities allotted
1800 Equity Shares - 9.76 Lakh raised
30 Aug 2022
Director ceased
XIAOHUI GUAN
Director ceased
YIFANG WU
20 Apr 2022
Director ceased
YAO FANG
26 Aug 2021
Director ceased
JIA AI ZHANG
17 May 2021
Director appointed
JIA AI ZHANG (Director)
Director appointed
NAINA LAL KIDWAI (Director)
Director ceased
NAINA LAL KIDWAI
10
Key Observations
Auto-generated from the data aboveRevenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
13 active director(s) / partner(s); review board churn before relying on management continuity.
8 active GST registration(s) indicate ongoing business operations.
All 11 registered charge(s) stand satisfied - past borrowings repaid.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a minority stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
6 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Akzonobel | L24292WB1954PLC021516 | Kolkata, West Bengal, India |
| Gacl | L24110GJ1973PLC002247 | Vadodara, Gujarat, India |
| The Fertilisers And Chemicals Travancore | L24129KL1943GOI000371 | Ernakulam, Kerala, India |
| Godrejindustries | L24241MH1988PLC097781 | Mumbai, Maharashtra, India |
| Natcopharma | L24230TG1981PLC003201 | Hyderabad, Telangana, India |
| Ajanta Pharma | L24230MH1979PLC022059 | Mumbai, Maharashtra, India |
| Emcure | L24231PN1981PLC024251 | Pune City, Maharashtra, India |
| Bbil | U24119KA2016PLC093936 | Bengaluru, Karnataka, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Gland Pharma before audits and certifications: compliance score 80/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Gland Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 75/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 80/100, margin trends, ownership structure and peer set for Gland Pharma - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 76/100, distress signals and MSME payment-delay disclosures - know whether Gland Pharma pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Gland Pharma - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Gland Pharma an active company?
Gland Pharma has MCA status “Active” with a compliance score of 80/100 (Low Risk).
Is Gland Pharma financially healthy?
Gland Pharma has a Financial Health Score of 75/100 (Low Risk) based on its filed financial statements.
Should I do business with Gland Pharma?
Its overall Trust Score is 76/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Gland Pharma?
The ultimate holding entity is Fosun Pharma Industrial Pte Ltd. 13 active director(s) are on record.
Does Gland Pharma have loans or charges against its assets?
No open charges - all 11 registered charge(s) stand satisfied, indicating past borrowings were repaid.
Is Gland Pharma up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 80/100 (Low Risk).
Is it risky to lend to Gland Pharma?
Its Credit Risk Score is 75/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
